LYSINE BIOTECH PRIVATE LIMITED
Product development and Manufacture of drugs, biomarkers and vaccines from Protein and DNA
CIN:U74999TN2018PTC122879
| S.No | LBPL drugs delivery (IND) | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | LBPL101 Kilirag-1 drug for treating type 2 diabetes in obese | 2025 | ||
| 2 | LBPL102 Ktictide-NPPA Congestive Heart Failure (IND) | 2025 | ||
| 3 | LBPL103 Kpondin1 (Spondin-1)- Alzheimer's (IND) | 2025 |
| S.No | LBPL Business model original pipelines 3rd generation of CAR-T cells | Research and Development | Preclinical Testing | Clinical and Commercial License (IP) |
| 1 | LBPL201 Product 3rd generation of CAR T-cell (Autologous) Target anti human scFv | 2025 | ||
| 2 | LBPL202 Product 3rd generation of CAR T-cell (Allogeneic) Target anti human scFv | 2026 | ||
| 3 | LBPL203 Product NeoAntigen Receptor-specific NeoAR T-cell receptors (TCRs) (Allogeneic) Target p53 | 2026 |
| S.No | LBPL Biosimliars mAbs Pipeline | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | LBPL301 Kembrolizumab (Pembrolizumab) | 2024 | ||
| 2 | LBPL302 Kculizumab (Eculizumab) | 2024 | ||
| 3 | LBPL303 Keriparatide (Teriparatide) | 2024 | ||
| 4 | LBPL304 Kdalimumab (Adalimumab) | 2024 | ||
| 5 | LBPL305 Kanibizumab (Ranibizumab) | 2024 | ||
| 6 | LBPL306 Kegfilgrastim (Pegfilgrastim) | 2024 | ||
| 7 | LBPL307 Kituximab (Rituximab) | 2024 | ||
| 8 | LBPL308 Kolimumab (Golimumab) | 2024 | ||
| 9 | LBPL309 Krastuzumab (Trastuzumab) | 2024 | ||
| 10 | LBPL310 Insulin Klargine (insulin glargine) | 2024 |
| S.No | LBPL Biobetters mAbs Pipeline | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | LBPL401 Kenralizumab (Benralizumab) | 2025 | ||
| 2 | LBPL402 Kaplacizumb (Caplacizumab) | 2025 | ||
| 3 | LBPL403 Kurvalumab (Durvalumab) | 2025 | ||
| 4 | LBPL404 Kemiplimab (Cemiplimab) | 2025 | ||
| 5 | LBPL405 Kbalizumab (Ibalizumab) | 2026 | ||
| 6 | LBPL406 Koxetumomab pasudodox (Moxetumomab pasudodox) | 2026 | ||
| 7 | LBPL407 Komosozumab (Romosozumab) | 2026 | ||
| 8 | LBPL408 Kisankizumab (Risankizumab) | 2026 | ||
| 9 | LBPL409 Krolucizumab (Brolucizumab) | 2026 | ||
| 10 | LBPL410 Krizanlizumab (Crizanlizumab) | 2026 |
| S.No | Lysvimab for RBD SPIKE COVID and RNA-Targeted small panantipeptide viral drugs for PAN-COVID | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | LBPLVIR501 Development of Alpha, Beta, Gamma, Delta, lamda & Omicron-specific Lysvimab-RBD SPIKE for treatment of COVID-19. | 2024 | ||
| 2 | LBPL502 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | 2027 | ||
| 3 | LBPL503 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | 2027 | ||
| 4 | LBPL504 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | 2027 |
| S.No | LBPLPANCOVAC-1 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based Recombinant Unique antigen peptide PANCOVAC and LBPLPANCOVIR-2 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | SARS-CoV-2 | 2027 | ||
| 2 | SARS-CoV-1 | 2027 | ||
| 3 | Human coronavirus OC43 | 2027 | ||
| 4 | Human coronavirus HKU1 | 2027 | ||
| 5 | Middle East respiratory syndrome-related coronavirus | 2027 | ||
| 6 | Infectious bronchitis coronavirus (Avian coronavirus) | 2027 | ||
| 7 | Turkey coronavirus (Avian coronavirus) | 2027 | ||
| 8 | Duck coronavirus (Avian coronavirus) | 2027 | ||
| 9 | Betacoronavirus HKU24 | 2027 | ||
| 10 | Bovine coronavirus isolate BCoV-ENT | 2027 | ||
| 11 | Betacoronavirus 1 | 2027 | ||
| 12 | Murine hepatitis virus strain MHV-A59 C12 mutant | 2027 | ||
| 13 | Canada goose coronavirus strain Cambridge_Bay_2017 | 2027 | ||
| 14 | Bulbul coronavirus HKU11 | 2027 | ||
| 15 | Rabbit coronavirus HKU14 | 2027 | ||
| 16 | Bat coronavirus BM48-31/BGR/2008 | 2027 | ||
| 17 | Tylonycteris bat coronavirus HKU4 | 2027 | ||
| 18 | Rousettus bat coronavirus isolate GCCDC1 356 | 2027 | ||
| 19 | Rousettus bat coronavirus HKU9 | 2027 | ||
| 20 | BtPa-BetaCoV/GD2013 | 2027 | ||
| 21 | BtRf-BetaCoV/HeB2013 | 2027 | ||
| 22 | BtRf-BetaCoV/JL2012 | 2027 | ||
| 23 | BtRf-BetaCoV/SX2013 | 2027 | ||
| 24 | BtRs-BetaCoV/GX2013 | 2027 | ||
| 25 | BtRs-BetaCoV/HuB2013 | 2027 | ||
| 26 | BtRs-BetaCoV/YN2013 | 2027 | ||
| 27 | BtTp-BetaCoV/GX2012 | 2027 | ||
| 28 | Bat Hp-betacoronavirus/Zhejiang2013 | 2027 | ||
| 29 | Betacoronavirus Erinaceus/VMC/DEU/2012 | 2027 | ||
| 30 | Pipistrellus bat coronavirus HKU5 | 2027 |
| S.No | LBPLPANCOVAC-2 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based Recombinant Unique PANCOVAC and LBPLPANCOVIR-3 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | Human coronavirus 229E | 2027 | ||
| 2 | Bat coronavirus | 2027 | ||
| 3 | Camel alphacoronavirus isolate camel/Riyadh/Ry141/2015 | 2027 | ||
| 4 | 229E-related bat coronavirus | 2027 | ||
| 5 | Unidentified human coronavirus | 2027 | ||
| 6 | Swine acute diarrhea syndrome related coronavirus | 2027 | ||
| 7 | Swine enteric alphacoronavirus | 2027 | ||
| 8 | Porcine enteric alphacoronavirus | 2027 | ||
| 9 | Rhinolophus bat coronavirus HKU2 | 2027 | ||
| 10 | Rhinolophus affinis bat coronavirus HKU2 | 2027 | ||
| 11 | Alpaca respiratory coronavirus | 2027 | ||
| 12 | BtRf-AlphaCoV/YN2012 | 2027 | ||
| 13 | Bottlenose dolphin coronavirus | 2027 | ||
| 14 | Bat alphacoronavirus | 2027 | ||
| 15 | Beluga Whale coronavirus SW1 | 2027 |
| S.No | LBPLPANCOVAC-3 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based Recombinant Unique PANCOVAC and LBPLPANCOVIR-4 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | Human coronavirus NL63 | 2027 | ||
| 2 | Ferret coronovirus | 2027 | ||
| 3 | Mink coronavirus strain WD1127 | 2027 | ||
| 4 | Bat coronavirus | 2027 | ||
| 5 | Miniopterus schreibersii bat coronavirus 1 | 2027 | ||
| 6 | Feline infectious peritonitis | 2027 | ||
| 7 | BtMr-AlphaCoV/SAX2011 | 2027 | ||
| 8 | BtRf-AlphaCoV/HuB2013 | 2027 | ||
| 9 | BtNv-AlphaCoV/SC2013 | 2027 | ||
| 10 | Bat coronavirus CDPHE15/USA/2006 | 2027 | ||
| 11 | Myotis lucifugus coronavirus | 2027 | ||
| 12 | Scotophilus kuhlii bat coronavirus 512 | 2027 | ||
| 13 | Transmissible gastroenteritis. | 2027 | ||
| 14 | Porcine epidemic diarrhea virus | 2027 | ||
| 15 | Lucheng Rn rat coronavirus isolate Lucheng-19 | 2027 | ||
| 16 | Bat coronavirus 1A | 2027 | ||
| 17 | Bat coronavirus 1B | 2027 | ||
| 18 | Bat coronavirus CDPHE15/USA/2006 | 2027 | ||
| 19 | Coronavirus AcCoV-JC34 | 2027 | ||
| 20 | Hipposideros pomona bat coronavirus CHB25 | 2027 | ||
| 21 | NL63-related bat coronavirus | 2027 | ||
| 22 | BtNv-AlphaCoV/SC2013 | 2027 | ||
| 23 | Rousettus bat coronavirus HKU10 | 2027 | ||
| 24 | Alphacoronavirus Bat-CoV/P.kuhlii/Italy/3398-19/2015 | 2027 | ||
| 25 | Wencheng Sm shrew coronavirus | 2027 |
| S.No | Protein subunit vaccine | Product Development | Preclinical Testing | Commercial License (IP) |
| 1 | LBPLVAC505 Protein subunit vaccine four in one Dengue 1-4 | 2025 | ||
| 2 | LBPLVAC506 Protein subunit Chikungunya vaccine | 2024 | ||
| 3 | LBPLVAC507 Protein subunit Sporozoite & Circumsporozoite vaccine (malaria) | 2024 | ||
| 4 | LBPLVAC508 Protein subunit monkeypox vaccine | 2023 | ||
| 5 | LBPLVAC509 Protein subunit Horsepox vaccine | 2023 | ||
| 6 | LBPLVAC510 Protein subunit Buffalopox vaccine | 2023 | ||
| 7 | LBPLVAC511 Protein subunit Vaccinia vaccine | 2023 | ||
| 8 | LBPLVAC512 Protein subunit Cowpox vaccine | 2023 | ||
| 9 | LBPLVAC513 Protein subunit insulin vaccine (SGIV) | 2024 |